info@biomedres.us   +1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Case ReportOpen Access

Treatment of Hepatitis C with Sofosbuvir, Velpatasvir and Voxilaprevir Decreases Hemoglobin A1c and Dependence on Anti-Glycemic Medications

Volume 9 - Issue 3

Kashif Aziz*1, Mehreen Khan2, Amir Shahbaz1, Muhammad Umair1 and Issac Sachmechi1

  • Author Information Open or Close
    • 1Department of Medicine, Icahn School of Medicine Mount Sinai, Queens Hospital Center, USA
    • 2School of Medicine and Public Health, the George Washington University School of Medicine, USA

    *Corresponding author: Kashif Aziz, Department of Medicine, Icahn School of Medicine Mount Sinai, Queens Hospital Center, Jamaica, New York, USA

Received: September 13, 2018;   Published: September 26, 2018

DOI: 10.26717/BJSTR.2018.09.001792

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Aim: Hepatitis treatment with direct acting antivirals improves markers of diabetes like HbA1c and also decreases daily requirement of anti-diabetic medications.

Background: Insulin resistance and Type 2 diabetes are one of manifestation of Hepatitis C (HCV). It is proposed that circulating micro ribonucleic acid (miRNA) can do regulatory functions to modulate gene expression in peripheral tissues leading to insulin resistance and diabetes. Clearance of HCV with direct‐acting antivirals (DAAs) significantly decreases hemoglobin A1c (HbA1c) and the dependence on anti‐glycemic medications.

Case Description: we present a case of HCV positive diabetic patient treated with the combination of sofosbuvir/velpatasvir/voxilaprevir, lead to improvement of his HbA1c as well as significant reduction of his daily insulin dose.

Conclusion: It is concluded that treatment of HCV with DAAs may cause improvement of glucose metabolism and decreases dependence on anti-diabetic medications.

Keywords: Hepatitis C; Sofosbuvir or Velpatasvir or Voxilaprevir; Hba1c; Type 2 Diabetes; Direct Acting Antiviral Agents

Abbreviations: HbA1c: Hemoglobin A1c; DAAs: Direct Acting Antivirals; HCV: Hepatitis C Virus; miRNA: Micro Ribonucleic Acid; CHC: Chronic Hepatitis C Virus Infection; SOF: Sofosbuvir; LED: Ledipasvir; Low LDL: Density Lipoprotein; SVR: Sustained Virologic Response

Abstract | Background | Case Report| Discussion | Conclusion | Protection of Humans and Animals| Data Confidentiality | Patient Consent | References|